The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations

European Journal of Clinical Pharmacology

Volumn 68, Issue 3, 2012, Pages 281-289

  Ingman, Kimmo ^a,c   Naukkarinen, Tarja ^a   Vahteristo, Mikko ^a   Korpela, Irja ^a   Kuoppamäki, Mikko ^a,b   Ellmén, Juha ^a  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c NONE   (Finland)

Author keywords

Dyskinesia; Entacapone; Levodopa; Parkinson's disease; Pharmacokinetics

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84857058642     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1121-5     Document Type: Article

References (14)

1. PA Lewitt 2008 Levodopa for the treatment of Parkinson's disease N Engl J Med 359 23 2468 2476 19052127 10.1056/NEJMct0800326 1:CAS:528: DC%2BD1cXhsVGns7jO
2. RA Hauser MP McDermott S Messing 2006 Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease Arch Neurol 63 12 1756 1760 17172616 10.1001/archneur.63.12.1756 (Pubitemid 44925085)
3. S Fahn 2000 The spectrum of levodopa-induced dyskinesias Ann Neurol 47 4 Suppl 1 S2 S9 10762127 1:STN:280:DC%2BD3c3it1Orsw%3D%3D discussion S9-S11
4. ES Tolosa WE Martin HP Cohen RL Jacobson 1975 Patterns of clinical response and plasma dopa levels in Parkinson's disease Neurology 25 2 177 183 1167646 1:STN:280:DyaE2M7gtVGlsg%3D%3D
5. Parkinson Study Group 1997 Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients Ann Neurol 42 5 747 755 10.1002/ana.410420511 (Pubitemid 27481547)
6. UK Rinne JP Larsen A Siden J Worm-Petersen 1998 Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. NOMECOMT Study Group Neurology 51 5 1309 1314 9818851 1:CAS:528:DyaK1cXns1emt7Y%3D (Pubitemid 28520549)
7. WH Poewe G Deuschl A Gordin ER Kultalahti M Leinonen 2002 Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study) Acta Neurol Scand 105 4 245 255 11939936 10.1034/j.1600-0404.2002.1o174.x 1:CAS:528:DC%2BD38XjvFGgs70%3D (Pubitemid 34407226)
8. DJ Brooks H Sagar 2003 Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study J Neurol Neurosurg Psychiatry 74 8 1071 1079 12876237 10.1136/jnnp.74.8.1071 1:STN:280:DC%2BD3szksVaisw%3D%3D (Pubitemid 36936383)
9. T Keränen A Gordin VP Harjola M Karlsson K Korpela PJ Pentikäinen H Rita L Seppalä T Wikberg 1993 The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers Clin Neuropharmacol 16 2 145 156 8477410 10.1097/00002826-199304000-00007 (Pubitemid 23090692)
10. M Kuoppamäki K Korpela R Marttila V Kaasinen P Hartikainen J Lyytinen S Kaakkola J Hänninen E Löyttyniemi M Kailajärvi P Ruokoniemi J Ellmén 2009 Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four- or five-times daily Eur J Clin Pharmacol 65 5 443 455 19229530 10.1007/s00228-009-0622-y
11. T Müller C Erdmann S Muhlack D Bremen H Przuntek D Woitalla 2006 Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels Mov Disord 21 3 332 336 16211593 10.1002/mds.20717
12. T Müller C Erdmann S Muhlack D Bremen H Przuntek O Goetze D Woitalla 2006 Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease J Neural Transm 113 1441 1448 16604302 10.1007/s00702-006-0442-5 (Pubitemid 44435882)
13. HM Ruottinen UK Rinne 1996 A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease Clin Neuropharmacol 19 4 283 296 8828991 10.1097/00002826-199619040-00001 1:CAS:528:DyaK28XltVahur4%3D (Pubitemid 26250111)
14. T Müller D Woitalla C Saft W Kuhn 2000 Levodopa in plasma correlates with body weight of parkinsonian patients Parkinsonism Relat Disord 6 3 171 173 10817957 10.1016/S1353-8020(00)00005-5 (Pubitemid 30246071)